An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection
Highly pathogenic avian influenza (HPAI) H5 viruses from different clades have been circulating globally, threatening wild/domestic birds and mammals. Given frequent spillovers and high mortality among mammals, coupled with our inability to predict which clade of H5 virus has pandemic potential, cross-clade protective HPAI H5 vaccines are urgently needed. Here, we demonstrate the applicability of a lipid nanoparticle-based mRNA vaccine modality to induce cross-protective immunity against lethal HPAI virus infection.
Authors
- Satoko Matsunaga
- Ryuta Uraki (ORCID: https://orcid.org/0000-0003-0890-1922)
- S. Chiba
- Aya Yamaguchi (ORCID: https://orcid.org/0000-0002-6521-6377)
- Seiya Yamayoshi (ORCID: https://orcid.org/0000-0001-7768-5157)
- Kiyoko Iwatsuki‐Horimoto (ORCID: https://orcid.org/0000-0002-8266-020X)
- Maki Kiso (ORCID: https://orcid.org/0009-0004-3645-0967)
- Yoshikuni Onodera
- Yoshihiro Kawaoka (ORCID: https://orcid.org/0000-0001-5061-8296)
- S. Yamada (ORCID: https://orcid.org/0000-0003-4808-893X)
- Kazuhiko Someya
- Fumihiko Takeshita (ORCID: https://orcid.org/0009-0001-7124-8877)
Institutions
- University of Wisconsin–Madison (US)
- Tokyo University of Science (JP)
- National Center for Global Health and Medicine (JP)
- Daiichi-Sankyo (Japan) (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- npj Vaccines
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1038/s41541-024-00988-9
- Citations
- 10
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.87
Funders
- Japan Agency for Medical Research and Development